Multifocal Motor Neuropathy (MMN)

Neurology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

argenx
argenxBelgium - Zwijnaarde
2 programs
1
1
EmpasiprubartPhase 31 trial
ARGX-117Phase 21 trial
Active Trials
NCT05405361Active Not Recruiting51Est. Sep 2029
NCT06742190Recruiting115Est. Dec 2029
CSL Behring
CSL BehringIL - Bradley
1 program
1
VivaglobinPhase 21 trial
Active Trials
NCT00701662Completed8Est. Jan 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
argenxEmpasiprubart
argenxARGX-117
CSL BehringVivaglobin

Clinical Trials (3)

Total enrollment: 174 patients across 3 trials

NCT06742190argenxEmpasiprubart

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Start: Dec 2024Est. completion: Dec 2029115 patients
Phase 3Recruiting

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Start: Jan 2023Est. completion: Sep 202951 patients
Phase 2Active Not Recruiting

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Start: Nov 2007Est. completion: Jan 20098 patients
Phase 2Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 174 patients
3 companies competing in this space